Kailera Therapeutics, Inc.

NasdaqGS:KLRA Stock Report

Market Cap: US$2.4b

Kailera Therapeutics Management

Management criteria checks 0/4

Kailera Therapeutics' CEO is Ron Renaud, appointed in Sep 2024, has a tenure of 1.92 years. total yearly compensation is $10.05M, comprised of 5.6% salary and 94.4% bonuses, including company stock and options. directly owns 0.029% of the company’s shares, worth $692.14K. The average tenure of the management team and the board of directors is 1.8 years and 1 years respectively.

Key information

Ron Renaud

Chief executive officer

US$10.0m

Total compensation

CEO salary percentage5.55%
CEO tenure1.9yrs
CEO ownership0.03%
Management average tenure1.8yrs
Board average tenure1yrs

Recent management updates

Recent updates

Seeking Alpha • Jul 09

Kailera Therapeutics: A Second-Wave Obesity Platform With More Than One Way To Win

Summary Kailera is building a multi-modal obesity franchise with exclusive global rights to Hengrui Pharma's obesity portfolio, leveraging late-stage assets and ongoing data. KLRA's robust cash position—over $1.3 billion post-IPO—funds operations through mid-2028, supporting multiple pivotal trial readouts before further capital is needed. Pipeline catalysts include global Phase 3 trials for ribupatide and promising Phase 2/3 data for oral GLP-1 candidates, targeting differentiated efficacy and convenience. I maintain a bullish outlook, as KLRA's diversified portfolio is well-positioned for a fragmented, high-growth obesity market despite competitive and translational risks. Read the full article on Seeking Alpha

CEO Compensation Analysis

How has Ron Renaud's remuneration changed compared to Kailera Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$210m

Dec 31 2025US$10mUS$558k

-US$149m

Compensation vs Market: Ron's total compensation ($USD10.05M) is above average for companies of similar size in the US market ($USD5.10M).

Compensation vs Earnings: Insufficient data to compare Ron's compensation with company performance.

CEO

Ron Renaud (57 yo)

1.9yrs
Tenure
US$10,049,306
Compensation

Mr. Ronald C. Renaud, Jr. also known as Ron, Jr., M.B.A., serves as President, Chief Executive Officer and Director at Kailera Therapeutics, Inc. since September 2024. He is Director of Cardurion Pharmaceu...

Leadership Team

NamePositionTenureCompensationOwnership
Ronald Renaud
President1.9yrsUS$10.05m0.029%
$ 692.1k
Paul Burgess
Chief Operating & Business Officer1.9yrsUS$2.37m0%
$ 0
Jamie Coleman
Chief Commercial Officer1.6yrsUS$3.67m0%
$ 0
Douglas Pagan
Chief Financial Officerless than a yearno datano data
Maura Gavaghan
Vice President of Corporate Communications & Investor Relationsno datano datano data
Scott Akamine
Chief Legal Officer & Secretary1.7yrsno datano data
Paula Cloghessy
Chief People Officer2.2yrsno datano data
Scott Wasserman
Chief Medical Officer1.8yrsno datano data
Kathleen Tregoning
Chief Corporate Affairs Officerless than a yearno datano data
Corey Manchester
Treasurerno datano datano data
1.8yrs
Average Tenure
54yo
Average Age

Experienced Management: KLRA's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Ronald Renaud
President1.9yrsUS$10.05m0.029%
$ 692.1k
John Milligan
Independent Non-Employee Chairman1.9yrsUS$1.71m0%
$ 0
Christopher Hite
Independent Non-Employee Director1.3yrsUS$791.73kno data
Adam Koppel
Independent Non-Employee Director1.3yrsno datano data
Martin MacKay
Independent Non-Employee Directorless than a yearno datano data
Andrew Kaplan
Independent Non-Employee Directorless than a yearno datano data
Franklin Clyburn
Independent Non-Employee Directorless than a yearUS$892.78kno data
Yuting Liu
Independent Non-Employee Directorless than a yearno datano data
1.0yrs
Average Tenure
58yo
Average Age

Experienced Board: KLRA's board of directors are not considered experienced ( 1 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/08/06 05:20
End of Day Share Price 2026/08/05 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Kailera Therapeutics, Inc. is covered by 6 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Umer RaffatEvercore ISI
Roger SongJefferies LLC
Hardik ParikhJ.P. Morgan